To read the full story, subscribe or sign in.

Hightide raises $107M series C to advance lead metabolic disease program to phase III

Jan. 10, 2023

Hightide Therapeutics Inc. closed a $107 million series C round that will advance multiple global development programs for lead candidate HTD-1801, including a phase III trial in type 2 diabetes.

BioWorld Asia Financings Diabetes Gastrointestinal Series C China

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...

Today's news in brief

BioWorld

BioWorld briefs for Feb. 3, 2023.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Feb. 3, 2022.

Setpoint Medical - vagus nerve stimulation device

Setpoint Medical lands up to $145M to advance RA implant

BioWorld MedTech

Bioelectronic medicine startup Setpoint Medical Corp. raised $80 million in a preferred stock financing co-led by new investors Norwest Venture Partners and...

Brain with clock hands, day and night background

12-Hour as well as circadian brain rhythms disrupted in people with schizophrenia

BioWorld Science

Research shows that individuals with schizophrenia have abnormal gene expression patterns in their brains compared with people without the condition. In a study...

Upgrade your daily dose of biopharma and medtech news

Hightide raises $107M series C to advance lead metabolic disease program to phase III